IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
38.41
-0.20 (-0.52%)
At close: Sep 18, 2026, 4:00 PM EDT
37.00
-1.41 (-3.67%)
After-hours: Sep 18, 2026, 7:30 PM EDT
IDEAYA Biosciences Revenue
IDEAYA Biosciences had revenue of $8.86M in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $234.13M, up 3,244.67% year-over-year. In the year 2025, IDEAYA Biosciences had annual revenue of $218.71M with 3,024.43% growth.
Revenue (ttm)
$234.13M
Revenue Growth
+3,244.67%
P/S Ratio
15.83
Revenue / Employee
$1,614,669
Employees
145
Market Cap
3.71B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 218.71M | 211.71M | 3,024.43% |
| Dec 31, 2024 | 7.00M | -16.39M | -70.07% |
| Dec 31, 2023 | 23.39M | -27.55M | -54.08% |
| Dec 31, 2022 | 50.93M | 22.99M | 82.28% |
| Dec 31, 2021 | 27.94M | 8.40M | 43.01% |
| Dec 31, 2020 | 19.54M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Legend Biotech | 1.27B |
| Tarsus Pharmaceuticals | 606.33M |
| Arcus Biosciences | 117.00M |
| AbCellera Biologics | 66.17M |
| Tango Therapeutics | 53.81M |
| Relay Therapeutics | 10.35M |
| Xenon Pharmaceuticals | 7.50M |
IDYA News
- 5 days ago - IDEAYA Biosciences Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 9 days ago - IDEAYA Biosciences Transcript: Citigroup’s Biopharma Back to School Summit 2026 - Transcripts
- 10 days ago - IDEAYA Biosciences Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 10 days ago - Ideaya Biosciences price target raised to $57 from $54 at Guggenheim - TheFly
- 10 days ago - Ideaya Biosciences doses first patient in OptimUM-11 trial - TheFly
- 10 days ago - IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma - PRNewsWire
- 11 days ago - IDEAYA Biosciences Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 18 days ago - IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences - PRNewsWire